Abstracts Archive - Page 2221 of 2425 - ACR Meeting Abstracts

Abstract Number: 432 • 2013 ACR/ARHP Annual Meeting
Use Of Rituximab As Second Line Biologic Agent Compared With Adalimumab, Etanercept and Infliximab In Patients With Rheumatoid Arthritis. a Report From The Rhumadata® Clinical Database and Registry
Louis Bessette¹, Denis Choquette², Diane Sauvageau³, Boulos Haraoui⁴, Jean Pierre Pelletier², Jean-Pierre Raynauld³, Edith Villeneuve³ and Louis Coupal², ¹Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁴Rhumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: The order of use of biologic agents after failing a TNF inhibitor is still a question for debate. Phase III trial data in TNF-IR…
Abstract Number: 433 • 2013 ACR/ARHP Annual Meeting
Retrospective Analysis Of Certolizumab Pegol Use During Pregnancy: Update Of Impact On Birth Outcomes
Megan E. B. Clowse¹, Douglas C. Wolf², Frauke Förger³, John J. Cush⁴, Christian Stach⁵, Gordana Kosutic⁶, Susan Williams⁶, Chidi Maduka⁶ and Uma Mahadevan⁷, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Atlanta Gastroenterology Associates, Atlanta, GA, ³Department of Rheumatology and Clinical Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland, ⁴Baylor Research Institute and Baylor University Medical Center, Dallas, TX, ⁵UCB Pharma, Monheim, Germany, ⁶UCB Pharma, Raleigh, NC, ⁷UCSF Medical Center, San Francisco, CA
Background/Purpose: Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF approved in 45 countries for the treatment of rheumatoid arthritis (RA) and/or Crohn's disease (CD). An…
Abstract Number: 434 • 2013 ACR/ARHP Annual Meeting
Results Of 64 Weeks Of Treatment With An Anti-IL-17 Antibody, Ixekizumab, In Patients With Rheumatoid Arthritis In a Phase 2 Study
Mark C. Genovese¹, Hilde Carlier², Janelle Erickson², Daniel Braun² and Subhashis Banerjee², ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Eli Lilly & Company, Indianapolis, IN
Background/Purpose: Ixekizumab, a monoclonal antibody that neutralizes IL-17A with high affinity and specificity, has been evaluated in patients (pts) with moderate to severe rheumatoid arthritis…
Abstract Number: 435 • 2013 ACR/ARHP Annual Meeting
Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized, Placebo-Controlled Trial Of Golimumab In Methotrexate-naïve Patients With Rheumatoid Arthritis
Paul Emery¹, Roy Fleischmann², Ingrid Strusberg³, Patrick Durez⁴, Peter Nash⁵, Eric Amante⁶, Melvin A. Churchill⁷, Won Park⁸, Bernardo Pons-Estel⁹, Chenglong Han¹⁰, Timothy A. Gathany¹⁰, Yiying Zhou¹¹, Stephen Xu¹² and Elizabeth C. Hsia¹², ¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and NIHR LMBRU, Leeds, United Kingdom, ²University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ³Instituto Reumatológico Strusberg, Cordoba, Argentina, ⁴Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, ⁵University of Queensland, Brisbane, Australia, ⁶University of Phillipines General Hospital, Manila, Philippines, ⁷Arthritis Center of Nebraska, Lincoln, NE, ⁸Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ⁹Sanatorio Parque, Rosario, Argentina, ¹⁰Janssen Global Services, LLC., Malvern, PA, ¹¹Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ¹²Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: Final 5yr safety and efficacy results of subcutaneous golimumab (GLM)+/-MTX evaluated in a phase 3 trial (GO-BEFORE) of MTX-naïve pts with rheumatoid arthritis (RA)…
Abstract Number: 436 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Study Of a Sequential Therapy Of Tocilizumab and, If Initially Inadequately Responded To Tocilizumab, Followed By Rituximab In Patients With Rheumatoid Arthritis and Inadequate Response To Traditional Disease Modifying Anti-Rheumatic Drugs (MIRAI)-Interim Analysis 2
Thomas Doerner¹, Hans Peter Tony², Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kaestner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, S. Wagner⁸, Marvin A. Peters⁹ and Christof Iking-Konert¹⁰, ¹Dept Int Med (Charite), Humdoldt Univ, Berlin, Germany, ²Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ³Division of Rheumatology, University of Munich, Munich, Germany, ⁴Ambulant Centres for Rheumatology, Rheumatologist, Ludwigsfelde, Germany, ⁵Outpatient Department of Rheumatology, Ambulantes Rheumazentrum Erfurt, Germany,, Erfurt, Germany, ⁶Centre for Inflammatory Joint Diseases, Munich, Germany, ⁷Rheumapraxis, Aachen, Germany, ⁸Internistische Schwerpunktpraxis für Rheumatologie, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰Department of Rheumatology, University Hospital Hamburg Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluates a sequential exposure to two defined biologics under rigorous study conditions within a homogeneous population of patients (pts) who inadequately…
Abstract Number: 437 • 2013 ACR/ARHP Annual Meeting
Patterns Of Use Of Oral and Subcutaneous Methotrexate Use In Rheumatoid Arthritis Patients Enrolled In The U.S. Medicare Program
Jeffrey R. Curtis¹, Fenglong Xie², Jie Zhang¹, Lang Chen³, Huifeng Yun⁴, Michael H. Schiff⁵, David Mackey⁶ and Seth Ginsberg⁷, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology Division, University of Colorado, Denver, CO, ⁶Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Creaky Joints, New York, NY
Background/Purpose: Although methotrexate (MTX) is the cornerstone of RA treatment, use of oral and subcutaneous (SC) preparations in real-world settings is not well characterized. Methods:…
Abstract Number: 438 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor, In A Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy In A Phase 3 Randomised Clinical Trial
M. C. Genovese¹, R. F. van Vollenhoven², B. Wilkinson³, L. Wang³, S. H. Zwillich³, D. Gruben³, B. Benda⁴ and T. V. Jones⁴, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Here, we describe the efficacy and safety for adalimumab (ADA)…
Abstract Number: 439 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Gastrointestinal Adverse Events Across The Rheumatoid Arthritis Clinical Program
E. B. Lee¹, J. R. Curtis², R. Riese³, C. A. Connell³, R. Chew³, M.G. Boy³, E. Maller⁴, C. Su⁴ and L. Wang³, ¹Seoul National University, Seoul, South Korea, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator in rheumatoid arthritis (RA). This analysis aimed to describe and…
Abstract Number: 403 • 2013 ACR/ARHP Annual Meeting
Peripheral Blood Biomarkers Of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Juan Chen¹ and Dana P. Ascherman², ¹Rheumatology, The First Afflicted Hospital of Xiamen University,, Xiamen,, China, ²Medicine/Rheumatology, University of Miami, Miami, FL
Background/Purpose: Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA) and a significant cause of morbidity and mortality. Asymptomatic, subclinical RA-associated…
Abstract Number: 412 • 2013 ACR/ARHP Annual Meeting
Clinical Characterization Of Extensive Interstitial Lung Disease In Rheumatoid Arthritis Patients
Masaomi Yamasaki, Rheumatology, Shin-Yokohama Yamasaki Clinic, Yokohama, Japan

Background/Purpose: To investigate clinical characteristics of interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients, and to analyze whether high resolutional CT (HRCT) can predict…
Abstract Number: 400 • 2013 ACR/ARHP Annual Meeting
Parotid Ultrasound Abnormalities Among Rheumatoid Arthritis Patients: Prevalence and Clinical Correlates
Hong Yang¹, Doquyen H. Huynh², Arnold Ceponis³ and Arthur Kavanaugh⁴, ¹Rheumatology, UCSD, San Diego, CA, ²Rheumatology, UC San Diego School of Medicine, San Diego, CA, ³Medicine/Rheumatology, University of California San Diego, La Jolla, CA, ⁴University of California San Diego, San Diego, CA
Background/Purpose: Sjögren's syndrome (SS) occurs commonly among rheumatoid arthritis (RA) patients. It may be an indicator of, and even a contributor to, increased RA disease…
Abstract Number: 401 • 2013 ACR/ARHP Annual Meeting
Chest Pain Is Not Associated With Coronary Atherosclerosis In Patients With Rheumatoid Arthritis and Ankylosing Spondylitis
Silvia Rollefstad¹, Eirik Ikdahl², Inge C. Olsen³, Jonny Hisdal⁴, Tore K. Kvien^5,6, Anne S. Eirheim², Terje R. Pedersen⁶ and Anne G. Semb², ¹Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Section of Vascular Investigations, Uslo University Hospital-Aker, Oslo, Norway, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Faculty of Medicine, University of Oslo, Oslo, Norway
Background/Purpose: During cardiovascular (CV) risk stratification in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS), it can be difficult to distinguish between chest pain…
Abstract Number: 402 • 2013 ACR/ARHP Annual Meeting
Can Modulators Of Inflammation Serve As Biomarkers For Subclinical Atherosclerosis In Rheumatoid Arthritis?
Kimberly P. Liang¹, Douglas P. Landsittel², Suresh R. Mulukutla³, Steven E. Reis⁴, Marc C. Levesque⁵, Donald M. Jones⁶, Rachel Gartland⁷, Ali Shoushtari⁸, Flordeliza S. Villanueva³, Hunter C. Champion⁸ and Larry W. Moreland⁵, ¹Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, Biostatistics and Clinical and Translational Science, University of Pittsburgh, Center for Health Care Research Data Center, Pittsburgh, PA, ³Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁴Division of Cardiology and Department of Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) is independently associated with a higher risk of cardiovascular disease (CVD) and premature atherosclerosis. Mechanisms of atherosclerosis include (1) Endothelial dysfunction/activation mediated…
Abstract Number: 404 • 2013 ACR/ARHP Annual Meeting
Arterial Stiffness Is Associated With Abnormal Left Ventricular Geometry In Patients With Rheumatoid Arthritis
Helga Midtbø¹, Eva Gerdts^1,2, Inge C. Olsen³, Tore K. Kvien⁴, Einar Davidsen¹ and Anne Grete Semb³, ¹Department of Heart Disease, Haukeland University Hospital, Bergen, Norway, ²Department of Cinical Science, University of Bergen, Bergen, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Rheumatoid arthritis (RA) predisposes for increased arterial stiffness(1). In hypertension, arterial stiffness is a powerful modulator of left ventricular (LV) geometry(2). Whether this is…
Abstract Number: 405 • 2013 ACR/ARHP Annual Meeting
Gout and RA: Not Such a Rare Coexistence After All
Christina Petsch¹, Elizabeth Araujo¹, Matthias Englbrecht¹, Axel J. Hueber², Georg Schett¹, Bernhard Manger¹ and Juergen Rech², ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: According to the current rheumatology literature, the simultaneous occurrence of rheumatoid arthritis (RA) and gout is rare and only a few cases have been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].